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Abstract: 
 
The third reading frame of the envelope gene from HIV-1 codes for a protein homologous to the 
human selenoprotein glutathione peroxidase (GPX). Cells stably or transiently transfected with a 
HIV-1 GPX construct are protected against the loss of the mitochondrial transmembrane 
potential and subsequent cell death induced by exogenous reactive oxygen species (ROS) as well 
as mitochondrion-generated ROS. However, HIV-1 GPX does not confer a general apoptosis 
resistance, because HIV-1 GPX-transfected cells were not protected against cell death induced 
by staurosporine or oligomycin. The inhibition of cell death induced by the ROS donor tert-
butylhydroperoxide was also observed in cells depleted from endogenous glutathione (GSH), 
suggesting that GSH is not the sole electron acceptor for HIV-1 GPX. Clinical HIV-1 isolates 
from long-term non-progressors (untreated patients with diagnosed HIV-1 infection for >10 
years, with CD4 T cell count of >500 cells/mm3) mostly possess an intact GPX gene (with only 
18% of loss-of-function mutations), while HIV-1 isolates from patients developing AIDS contain 
non-functional GPX mutants in 9 out of 17 cases (53%). Altogether, these data suggest that HIV-
1 GPX possesses a cytoprotective, pathophysiologically relevant function. 
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butylhydroperoxide. 
 
Introduction 
 
Human immunodeficiency virus-1 (HIV-1) merciless exploits the host cell to guarantee its 
replication and propagation. One of the major pathways targeted by HIV-1 is the apoptotic 
machinery.1–3 Indeed, the temporary suppression of apoptosis of HIV-1 infected cells is a 
conditio sine qua non for HIV-1 to replicate and to constitute the viral reservoir. In contrast, the 
induction of apoptosis may ultimately participate in viral spreading and certainly contributes to 
the subversion of the immune system by HIV-1.1–3 An increased apoptotic turnover of immune 
cells constitutes a hallmark of HIV-1 infection. Thus, an enhanced propensity of CD4+ 
lymphocytes to undergo apoptosis in vitro is associated with progressive disease,4–6 and this 
laboratory parameter is one of the first to improve when patients are treated successfully with 
highly active anti-retroviral therapy (HAART).7–11 Similarly, patients developing the acquired 
immunodeficiency syndrome (AIDS) manifest an increased percentage of circulating CD4+ T 
cells with a reduced mitochondrial transmembrane potential (ΔΨm),12,13 one of the hallmarks of 
imminent or ongoing apoptosis.14–17 In contrast, so-called long-term non-progressors (LTNP), 
patients not receiving any anti-retroviral therapy who do not develop lymphodepletion (CD4 T 
cell count of >500 cells mm3) within 10 years after primoinfection, exhibit a low propensity of T 
cells to undergo apoptosis in vitro18 and a normal, low percentage of circulating cells with a 
reduced ΔΨm .13 This phenotype correlates with a specific loss-of-function mutation of the HIV-
1 encoded proapoptotic protein Vpr,19 a mutation that is found in 81% of LTNP.18 Thus viral 
mutations in apoptosis-regulatory proteins may determine HIV-1 virulence and, ultimately, the 
patient’s fate.20 
 
HIV-1-infected cells manifest a shift in the redox balance, with an increased production of 
reactive oxygen species,21,22 as well as a depletion of anti-oxidant metabolites such as glutathione 
(GSH),21 a condition which is likely to augment the propensity of cells to undergo apoptosis.23–25 
Similarly, circulating lymphocytes from HIV-1 infected donors tend to produce elevated levels 
of reactive oxygen species (ROS),26 a fraction of which, at least, is produced by deregulated 
mitochondria.12 Reduced circulating levels of GSH indicate a poor clinical prognosis,27,28 and 
several authors advocate the therapeutic supplementation of anti-oxidant compounds 29 including 
N-acetyl cysteine, a GSH precursor 28,30 and selenium (Se).31 
 
Recently, it has been reported that HIV-1 would encode a GSH peroxidase (GPX),32 an enzyme 
that detoxifies peroxide radicals while oxidizing glutathione. Thus, the third reading frame of the 
envelope (Env) gene (which itself is largely pro-apoptotic)33 encodes a putative selenoprotein, 
that is a protein which contains a catalytic selenocysteine (Sec) residue.32 In addition, HIV-GPX 
bears structural similarities with mammalian GPX, including the catalytic triad selenocysteine 
(U), Gln (Q) and Trp (W), as well as the overall GPX fold, as deduced from computerized 
calculations.32 On theoretical grounds, the existence of such an HIV-1 GPX may explain the 
tendency of host-cell selenoproteins to be underexpressed, as a consequence of competition for 
the oligoelement Se.34,35 Since such selenoproteins are mostly anti-oxidant enzymes (in particular 
GSH peroxidases and thioredoxin reductases), this would lead to reduction of the anti-oxidant 
defense of the host cell organism.35 Conversely, it is possible that HIV-1 GPX might exert a 
catalytic activity that itself enhances the anti-oxidant system of the host cell,32 as this has been 
reported for a GPX encoded by molluscum conagiosum virus.36 
 
Intrigued by these possibilities, we decided to explore the putative apoptosis-modulatory 
function of HIV-1 GPX. Here, we show that mammalian cells manipulated to express the HIV-1 
GPX gene exhibit a relative resistance against exogenous ROS as well as ROS produced by 
mitochondria, leading to a selective apoptosis resistance. Moreover, we show that viral isolates 
from patients with progressive disease carry HIV-1 strains with loss-of-function mutations in the 
GPX gene. These findings may have major implications for the pathophysiology of HIV-1 
infection. 
 
Materials and methods 
 
Sequence analysis 
 
HIV-1 sequences were obtained from the Los Alamos AIDS data base and were analyzed by 
using the BLAST program (NCBI). 
 
Cell culture, transfection, and apoptosis induction 
 
The MDCK (Madi Darbin Canine Kidney) cell line stably transfected with the histidine tagged 
HIV-1 Gpx protein (pHGD), as well as control cells transfected with vector only (pC2) were 
described previously.32 The nonmanipulated MDCK cell line was obtained from the American 
Type Culture Collection (ATCC). All cell types were grown under 5% CO2 at 37°C in DMEM 
medium supplemented with 2 mM glutamine, 10% newborn calf serum, 1 mM pyruvate, 10 mM 
Hepes, 100 U/ml pencillin/streptomycin and 5 μg/ml gentamycin (GIBCO). MDCK cells were 
transfected by using Polyfect reagent (Quiagen), on six-well plates, with each well seeded with 
2.5×105 cells and 5 μg of plasmid DNA. 24 hours post-transfection, transfected cells were 
selected for antibiotic resistance to G418 at 400 μg/ml, by changing G418-containing medium 
every 3 days for 21–30 days. 
 
Induction and quantification of apoptosis 
 
For cell death induction, 5×104 cell were grown overnight on six-well plates and treated with 
various doses of ter-butylhydroperoxide, stauroporine, antimycin A, oligomycin (Sigma) during 
an overnight incubation at 37°C. BSO was used at a concentration of 100 μM to deplete 
endogenous GSH levels, 24 h before apoptosis induction. All chemicals reagents were purchased 
from Sigma. The following fluorochromes (Molecular Probes) were employed to assess 
apoptosis-associated changes by cytofluorometry on a FACS Vantage (Becton Dickonson), 
while gating the forward and the side scatters on viable cells: 3,3′ dihexyloxacarbocyanine iodide 
(DiOC6(3), 40 nM; 15 min at 37°C) or tetramethylrhodamine ethyl ester (TMRE, 150 nM; 15 
min at 37°C) for ΔΨm quantification, propidium iodide (PI, 1 μg/ml) for the determination cell 
viability.37 The generation of ROS was monitored with hydroethidine (HE, 2 μM; 15 min at 
37°C). Labeling with Annexin V-FITC conjugate (5 μl; Pharmingen, San Diego, CA) to assess of 
the aberrant phosphatidylserine (PS) residues exposure, was performed as described.37 The 
content in free thiols (mainly GSH) was determined using monochlorobimane (MCB, 50 μM).23 
 
Construction of the pIRES-HGD 
 
Six histidine residues have been incorporated between the Met start codon and the Gly residue 
that is at the N-terminal end of the putative GPX sequence in order to obtain a histidine tagged 
HIV-l GPX. Furthermore, since the selenocysteine insertion in eukaryotic selenoproteins 
involves an RNA stem-loop structure called a selenocysteine insertion sequence (SECIS) 
element in the 3′-untranslated region of the mRNA, the His-HIV-l GPX has been fused to the 
SECIS element of the rat 5′-deiodinase (5′-DI).32 This His-HIV-l GPX-5′-DI SECIS construct 
(termed HGD) was subcloned into the pEGFPC1 vector. The HGD insert was exised from 
pEGFPC1 as an NheI-BamHI fragment and ligated into the pIRES-EGFP (Clontech) vector 
digested by the same enzymes to obtain pIRES-HGD. The quality of DNA subcloning was 
confirmed by DNA sequencing. The E. coli DH5 α strain was used to propagate various plasmids 
and their derivatives. 
 
RNA isolation and RT-PCR reaction 
 
1×106 cell stably transfected with pIRES or pIRES-HGD were grown during 2 days in the 
presence or absence of selenium (20 nM). Cells were washed twice in PBS and RNA were 
purified with the RNeasy extraction kit (QIAGEN). After a reverse transcriptase polymerase 
chain reaction (RT-PCR) amplification using the following primers: 5′- primer 5′-
CGGAATTCGTGCATCATCATCAT-3′ and 3′-primer: 5′-
GCGGATCCCGGATTTTAATCGTT-3′, corresponding to the HGD sequence (Oligo Gpx) and 
the 3′-primer: 5′-ATGGTGAGCAAGGGCGAGGAG-3′ as control (Oligo Co). Primers 
corresponding to the β-Actine RNA present in the RT-PCR kit were used as control for the 
efficacity of the reaction. All amplified DNA fragments were visualized by agarose gel 
electrophoresis. 
 
Results and discussion 
 
Conservation of the HIV-1 GPX gene among clinical HIV-1 isolates 
 
The third reading frame of the Env gene codes for a putative GPX selenoprotein.32 HIV-1 GPX 
amino acid sequences obtained from primary HIV-1 isolates, either from patients with 
progressive disease or from long-term non-progressors (LTNP) were obtained from public data 
bases and aligned. As shown in Figure 1, the HIV-1 GPX gene was well conserved among most 
long-term nonprogressors (LTNP), that is HIV-1 infected individuals which, without any 
treatment, remain essentially disease-free with normal CD4+ counts. Only in two of the eleven 
LTNP isolates, stop codons were found to truncate the protein. In contrast, 59% of clinical 
isolates obtained from progressors manifested either a substitution of the critical HIV-1 GPX 
selenocysteine residue (marked as “U” within the R1 domain) and/or a truncation due to stop 
codons in the N-terminus of the protein, within the functionally important R2 region, or at the N-
terminus of the R3 region, meaning that the enzymatic function of the protein must be lost 
(Figure 1). Of note, all but two of the GPX genes derived from patients developing AIDS (15 
among 17) exhibited non-conservative mutations in the R1 region (32 non-conservative 
replacements among 160 residues), while none (0 among 100 residues) of the R1 regions from 
LTNPs was mutated (Figure 1). Thus, the HIV-1 GPX gene appears to be conserved in 
laboratory strains of HIV-1, as well as in LTNP isolates, while loss-of-mutations affect a 
majority of HIV isolates from patients with progressive disease. 
 
 
Figure 1. Comparison of GPX sequences in different HIV-1 isolates. The open reading frame encoding for the 
putative GPX protein was located in the third reading frame of the Env gene from different HIV-1 isolates, obtained 
from patients that develop AIDS (progressors) as well as from long-term non-progressors (LTNP). R1 (boxed) 
contains the selenocysteine residue (denoted as “U”), while R2 and R3 contain additional conserved active-site 
regions. The Env-fs sequence is the consensus GPX sequence from HIV-1LAI reported in Ref. 32. Note that several 
GPX proteins deduced from virulent HIV-1 isolated have mutated the selenocysteine-encoding UGA to arginine 
(AGA) and possess a stop codon leading to a truncation that is incompatible with the redox function of the enzyme. 
Conservative amino acid changes are depicted in green, while non-conservative changes are labeled in red. The 
GenBank accession codes of each HIV-1 isolate are indicated. 
 
Selective apoptosis resistance conferred by stably expressed HIV-1 GPX 
 
Cells stably transfected with an HIV-1 GPX construct engineered to contain the selenocysteine 
insertion sequence (SECIS) element in the 3′ untranslated region32 (pHGD cells), as well as 
vector-only control cells (pC2 cells), were cultured in the absence or presence of the trace 
element Se (provided as sodium selenite) and exposed to the general apoptosis inducer 
staurosporine (STS) or the ROS donor tert-butylhydroperoxide (t-BHP), followed by 
determination of several parameters of apoptosis: the dissipation of the ΔΨm (quantified with the 
ΔΨm -sensitive dye DiOC6(3)), the cell-autonomous generation of ROS (quantified with 
hydroethidine [HE], a non-fluorescent plasma membrane-permeable compound that is oxidized 
by ROS to ethidium [Eth], a fluorescent, hydrophilic compound that is trapped in the cell) 
(Figure 2A), the exposure of phosphatidylserine moieties on the plasma membrane surface 
(quantified with Annexin V-FITC conjugates), and the loss of viability (quantified with the vital 
dye propidium iodide) (Figure 3A). Selenite conferred a relative resistance against t-BHP, in 
accord with its apoptosis-inhibitory effect.38,39 Cells expressing HIV-1 GPX (pHGD) were more 
resistant against low doses of t-BHP than control cells, and this effect was more pronounced in 
the presence of Se than in its absence. Thus, a depletion of Se from endogenous selenoproteins 
cannot account for the apoptosis-modulatory effect of GPX. Neither Se nor GPX conferred any 
protection against STS-induced cell death (Figures 2 and 3). The selective HIV-1 GPX-mediated 
inhibition of t-BHP (but not STS)-induced cell death was detectable with all four read-outs of 
apoptosis induction (ΔΨm loss and ROS overproduction in Figure 2, phosphatidylserine exposure 
and plasma membrane permeabilization in Figure 3). 
 
Apoptosis resistance conferred by HIV-1 GPX in transient transfection experiments 
 
In stably transfected cell lines, cloning artifacts or epigenetic phenomena with alterations in the 
transcriptome might influence the experimental outcome. We therefore decided to clone HIV-
GPX into a pIRES vector that leads to the joint transcription/translation of HIV-1 GPX and green 
fluorescent protein (GFP) from the same mRNA species. As shown in Figure 4a, the addition of 
an external source of Se did not influence the level of GFP expression, suggesting that the 
stability of the HIV-1 GPX mRNA is not influenced by Se. FACS purification of cells transiently 
transfected with HIV-1 GPX plus GFP (and as a negative control, cells that only express GFP 
encoded by the pIRES vector) (Figure 4b), followed by RT-PCR revealed that the cells indeed 
expressed HIV-1 GPX mRNA (Figure 4c) that was unmutated (not shown). In transient 
transfection experiments, HIV-1 GPX did confer a significant protection against t-BHP-induced 
ΔΨm loss (quantified with tetramethylrhodamine ester, TMRE, Figure 5a) and cell death 
(quantified with PI, Figure 5b). Thus, HIV-1 GPXis functionally relevant for cell survival in 
conditions of ROS-mediated stress. 
 
HIV-1 GPX inhibits apoptosis induced by mitochondrion-generated ROS 
 
The experiments described above involved the addition of an exogenous source of ROS. To 
investigate whether HIV-1 GPX also inhibits apoptosis induced by endogenous ROS (which are 
mostly produced by mitochondria), we took advantage of antimycin A (Ant A), an inhibitor of 
respiratory chain complex III that stimulates the production of ROS.40 Addition of antimycin A 
led to a global shift in the production of HE-detectable ROS, which was not influenced by Se or 
HIV-1 GPX (Figure 6a). The antimycin A-induced ΔΨm loss was not or only marginally 
influenced by Se, yet was strongly inhibited by HIV-1 GPX (Figure 6a and b). In sharp contrast, 
HIV-1 GPX did not protect against the cytotoxic effect of oligomycin, an inhibitor of complex 
V(F1/0 ATPase) that does not trigger ROS overproduction (Figure 6a and b). Altogether, these 
data indicate that HIV-1 GPX can protect cells against ROS produced from an endogenous 
source and confirm the selective apoptosis-modulatory function of HIV-1 GPX. 
 
 
 
Figure 2. Anti-apoptotic action of GPX as assessed by evaluation of the mitochondrial transmembrane potential 
(ΔΨm). MDCK cell lines stably transfected with vector only (pC2) or with an HIV-1-encoding GPX construct 
(pHGD) were cultured in the absence (−Se) or presence (+Se) of 20 nM selenium, as well as the indicated doses of 
staurosporine (STS) and the ROS donor tert-butylhydroperoxide (t-BHP). Eighteen hours later cells were 
trypsinized and stained with a combination of two fluorochromes, namely DiOC6(3) (which is ΔΨm -sensitive) and 
hydroethidine (HE, which is non-fluorescent, yet emits a fluorescence upon oxidation to ethidium, Eth), followed by 
cytofluorometric analysis. Original FACS diagrams are depicted in A. Note that the (HE→Eth)high cells constitute a 
fraction of DiOC6(3)low cells. Mean values of eight independent experiments (X±SEM) are shown in B. Arrows 
denote significant (p < 0.05) differences between cells tranfected with HIV-1 GPX or not. 
 
 
Figure 3. Anti-apoptotic action of GPX as assessed by assessment of phosphatidylserine exposure on the cell 
surface. The experimental setup was similar to that described in Figure 2, with the difference that apoptosis was 
assessed by staining with annexin V-FITC conjugates plus the vital dye propidium iodide. Original FACS 
pictograms are shown in A, while the pooled data from six independent experiments (X±SEM) are shown in B. 
Arrows denote significant (p < 0.05) differences between cells transfected with HIV-1 GPX or not. 
 
 
 
Figure 4. Characterization of MDCK cells transiently transfected with a vector coding for both GFP and HIV-1 
GPX. MDCK were either mock transfected or transfected with a vector encoding GFP alone (pIRES) or a vector 
coding for both GFP and HIV-1 GPX (pIRESGPX). Cells were cultured either in the presence or in the absence of 
Se, followed by FACS analysis to detect GFP expression (in FL1), 48 h after transfection (A). Numbers refer to the 
percentage of cells positive for GFP. Cells found positive for GPF (gates in A) were FACS-purified and re-analyzed 
in the cytofluorometer to assess the purity of the population (B). Such FACS-purified cells transfected with either 
the pIRES or the pIRES-GPX construct, cultured in the absence or in the presence of Se, were subjected to RT-PCR 
analysis using suitable primers for the detection of HIV-1 GPX or β-actin. 
  
Figure 5. Transient expression of HIV-1 GPX confers resistance against t-BHP. MDCK cells transfected with the 
pIRES vector alone (which encodes GFP) or the pIRES-HGD construct (which encodes GFP plus HIV-1 GPX) were 
treated with the indicated concentrations of t-BHP, in the presence or absence of 20 nM Se. After overnight 
incubation the cells were stained with the ΔΨm -sensitive dye TMRE or PI, and the frequency of cells exhibiting a 
low ΔΨm (and hence a low TMRE fluorescence) or a permeable plasma membrane (and hence incorporation of PI) 
was determined while gating on the population of cells expressing GFP as in Figure 4. Results are mean values of 
five different experiments. Arrows denote significant (p < 0.01) differences between cells tranfected with pIRES-
HGD or pIRES vector only. 
 
GSH-independent anti-apoptotic potential of HIV-1 GPX 
 
If reduced GSH was the unique electron acceptor of HIV-1 GPX, the protein should lose its anti-
oxidant (and hence anti-apoptotic) function in conditions in which GSH is depleted. We 
therefore depleted GSH by pretreating pHGD and pC2 cells with buthionine sulfoximine (BSO), 
an inhibitor of GSH synthesis, while controlling effective GSH depletion with monochlorobiman 
(MCB) staining (Figure 7c). As to be expected, GSH depletion enhanced the susceptibility of 
both pC2 and pHGD cells to t-BHP-induced ΔΨm loss (Figure 7a) and cell death (Figure 7b). 
Surprisingly, however, even in the absence of endogenous GSH, pHGD cells remained relatively 
resistant (as compared to pC2 cells) against the ΔΨm loss induced by to t-BHP. Thus, HIV-1 
GPX protects against ROS-induced apoptosis in conditions in which GSH is depleted. 
 
Concluding remarks 
 
The data presented in this paper indicate that the putative HIV-1 GPX may well have an 
important anti-apoptotic function, conferring cytoprotection against exogenous or endogenous 
ROS. HIV-1 possesses several proteins which induce apoptosis via redox-sensitive effects. Thus, 
Tat has been shown to interfere with the expression and/or function of the potent ROS 
detoxifying enzyme superoxide dismutase-2,41 and Vpr can perturb mitochondrial function by 
inhibiting the adenine nucleotide translocase,42 an effect that reportedly leads to the 
overproduction of ROS.43 Detoxification of ROS by a virus-encoded GPX may antagonize 
apoptosis in infected cells, perhaps facilitating viral replication. Indeed, apoptosis inhibition by 
overexpression of Bcl-2 or caspase inhibition can enhance HIV-1 replication in culture,44–47 and 
it is well possible that the HIV-1 GPX exerts a similar effect, in line with the fact that laboratory 
strains of HIV-1 tend to possess an intact GPX gene (like the HIV-1LAI isolated shown in Figure 
1). 
 
 
 
Figure 6. HIV-1 GPX confers resistance against apoptosis induced by mitochondrial ROS. MDCK cells stably 
transduced with the control vector (pC2) or the HIV-1 GPX construct (pHGD) were cultured in the absence or 
presence of Se and exposed to the indicated doses of antimycin A or oligomycin for 18 h followed by staining with 
the ΔΨm-sensitive dye DiOC6(3) and the ROS-sensitive dye HE. Representative FACS diagrams are shown in A, 
and mean values (X±SEM) from five different experiments are shown in B. Asterisks denote a significant protective 
effect conferred by HIV-1 GPX. 
 
Figure 7. Effect of GSH depletion on cell death induced by t-BHP. Control (pC2) or HIV-1 GPX-transfected cells 
(pHGD) were pretreated with buthionine sulfoximine (BSO), an inhibitor of GSH synthesis, for 24 h and then 
exposed to the indicated dose of t-BHP. After a further incubation period of 18 h, the frequence of cells with a low 
ΔΨm (determined by staining with DiOC6(3)) and a permeable plasma membrane (determined by staining with PI) 
was assessed by cytofluorometry. In addition, the degree of GSH depletion was measured with monochlorobiman 
(MCB), which emits fluorescence upon formation of GSH adducts. This experiment was repeated three times with 
comparable results. 
 
It remains on ongoing conundrum which are the optimal electron acceptors used by HIV-1 GPX. 
In BSO-treated cells depleted from GSH (as determined by MCB staining), HIV-1 GPX 
continues to be an efficient antiapoptotic factor. This suggests that HIV-1 GPX may transfer 
electron on other acceptors such as thioredoxin or redox-active disulfides, as this has been shown 
for several human GPX isoforms.48,49 Alternatively, the Kd of HIV-1 GPX for GSH might be that 
low that trace amounts of GSH would be sufficient to maintain its ROS-detoxifying role. 
However, mammalian GPX have a Kd for GSH in the range of 10−5 to 10−4 M,50 which argues 
against this latter possibility. However, it appears that the overall GPX fold and the 
selenocysteine play an essential role in the anti-apoptotic function of GPX since mutations of 
structural residues (such as P55S), stop mutations within R2 (such as Q52STOP), and removal of 
the SECIS sequence (essential for the synthesis of the selenocysteine) destroy the anti-apoptotic 
function of HIV-1GPX(Ref. 32 and data not shown). 
 
That the HIV-1 GPX is essential for viral infection, at some stage, is suggested by the fact that 
the protein is well conserved among different virus strains, among LTNP. Our data indicate that, 
among different HIV-1 strains from LTNP, the third nucleotide within each codon of the Env 
gene (hence the first nucleotide of each triplet coding for HIV-1 GPX) is much more conserved 
within the region coding for HIV-GPX (with only 1.67 ± 0.15% [X ± SEM] nucleotide 
exchanges among the sequences shown in Figure 1) than outside of this region (3.43 ± 0.33%, p 
< 0.001, paired Student t test). Given the notorious propensity of HIV-1 to mutate, the only 
explanation for such a degree of conservation is its vital role for HIV-1 infection, at some stage 
of the viral life cycle. In contrast, in patients developing AIDS, this difference in conservation 
disappeared, with 4.33 ± 0.47% exchanges of the third nucleotide in the region of the Env gene 
corresponding to HIV-GPX versus 4.77 ± 0.43% exchanges outside this region (data for the 
HIV-1 isolates in Figure 1, excluding the hypermutated isolates AJ302646, AJ0006022 and 
L20571). It appears paradoxical that HIV-1 isolates from LTNP tend to have a more conserved 
GPX gene than HIV-1 isolated from individuals developing AIDS. As a possible explanation, 
loss-of-function of GPX may increase the apoptosis-inducing potential of HIV-1, thereby 
contributing to terminal lymphodepletion. Thus, as a tantalizing mirror image, the pro-apoptotic 
function of the Vpr protein would be maintained during the progression to AIDS (yet inactivated 
in LTNP), while the anti-apoptotic function of GPX would be lost in progressive disease (and 
conserved in LTNP). 
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